BR112012028766A2 - processo para a preparação de complexos de insulina e zinco - Google Patents

processo para a preparação de complexos de insulina e zinco

Info

Publication number
BR112012028766A2
BR112012028766A2 BR112012028766A BR112012028766A BR112012028766A2 BR 112012028766 A2 BR112012028766 A2 BR 112012028766A2 BR 112012028766 A BR112012028766 A BR 112012028766A BR 112012028766 A BR112012028766 A BR 112012028766A BR 112012028766 A2 BR112012028766 A2 BR 112012028766A2
Authority
BR
Brazil
Prior art keywords
insulin
preparation
zinc complexes
solution
insulin derivative
Prior art date
Application number
BR112012028766A
Other languages
English (en)
Portuguese (pt)
Inventor
Andresen Lene
Jeppesen Per
Rebecca Erritzoe Hansen Rosa
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112012028766A2 publication Critical patent/BR112012028766A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112012028766A 2010-05-10 2011-05-09 processo para a preparação de complexos de insulina e zinco BR112012028766A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10162368 2010-05-10
US33349710P 2010-05-11 2010-05-11
PCT/EP2011/057388 WO2011141407A1 (en) 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes

Publications (1)

Publication Number Publication Date
BR112012028766A2 true BR112012028766A2 (pt) 2017-06-13

Family

ID=42732779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028766A BR112012028766A2 (pt) 2010-05-10 2011-05-09 processo para a preparação de complexos de insulina e zinco

Country Status (12)

Country Link
US (5) US20130143803A1 (https=)
EP (1) EP2569002B1 (https=)
JP (2) JP6249773B2 (https=)
KR (2) KR20160105979A (https=)
CN (2) CN102883743A (https=)
AU (1) AU2011252127B2 (https=)
BR (1) BR112012028766A2 (https=)
CA (1) CA2795091A1 (https=)
ES (1) ES2612468T3 (https=)
MX (1) MX2012012943A (https=)
RU (1) RU2572214C2 (https=)
WO (1) WO2011141407A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー/エス インスリン組成物および組成物の製造方法
EP1991576B1 (en) 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー/エス インスリン投薬レジメン
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー/エス 新規投与レジメン
AU2014333979B2 (en) * 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2019110797A1 (fr) * 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019110788A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CN111315766B (zh) * 2018-02-01 2023-05-12 江苏恒瑞医药股份有限公司 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
SG11202106167XA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin conjugates
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) * 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) * 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
CZ287945B6 (cs) * 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
SI2107069T1 (sl) * 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
JP4808785B2 (ja) * 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー/エス インスリン組成物および組成物の製造方法
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
ES2612468T3 (es) 2017-05-17
US20130143803A1 (en) 2013-06-06
US20240307503A1 (en) 2024-09-19
AU2011252127A1 (en) 2012-11-01
JP6249773B2 (ja) 2017-12-20
AU2011252127B2 (en) 2014-02-20
MX2012012943A (es) 2012-11-29
EP2569002A1 (en) 2013-03-20
US20150250857A1 (en) 2015-09-10
KR20160105979A (ko) 2016-09-08
US20210060132A1 (en) 2021-03-04
CA2795091A1 (en) 2011-11-17
US20170165327A1 (en) 2017-06-15
WO2011141407A1 (en) 2011-11-17
KR20130092972A (ko) 2013-08-21
CN102883743A (zh) 2013-01-16
JP2013526501A (ja) 2013-06-24
EP2569002B1 (en) 2016-10-26
CN107029212A (zh) 2017-08-11
JP2017203042A (ja) 2017-11-16
RU2572214C2 (ru) 2015-12-27
RU2012148821A (ru) 2014-06-20

Similar Documents

Publication Publication Date Title
BR112012028766A2 (pt) processo para a preparação de complexos de insulina e zinco
MY160249A (en) Fatty acid fumarate derivatives and their uses
AU2018260825A1 (en) Compositions and Methods for Lowering Levels of High-Sensitivity (hs-CRP) in a Subject
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BR112013000675A2 (pt) nanopartícula, processo para produzir uma nanopartícula compreendendo uma matriz de zeína e um aminoácido básico, processo para produzir uma nanopartícula compreendendo uma matriz de zeína, e um aminoácido básico e um composto biologicamente ativo solúvel em gordura, composição e produto alimentar
NZ732777A (en) Ionizable cationic lipid for rna delivery
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
CU20130137A7 (es) Derivados de ácido 3- fenilpropiónico ramificados y su uso
EA201201648A1 (ru) Стимуляторы sgc
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
AR081060A1 (es) Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BRPI0918360A8 (pt) Composto, composição farmacêutica e usos de um composto
BR112012014151A8 (pt) produto de proteína e processo para a preparação de um produto de proteína injetável
MX387845B (es) Polímeros enlazados al proton para administracion oral.
AU2012245910A8 (en) Microfluidic system for controlling the concentration of molecules for stimulating a target
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
EA201490175A1 (ru) Составы дезоксихолевой кислоты и ее солей
AU2015275248B2 (en) Legumain activated doxorubicin derivative as well as preparation method and application thereof
PH12015502556A1 (en) Modified release formulation
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]